Lymphoma in dogs and cats in India: the four forms, the staging, what a CHOP course actually buys, and where it can be treated

Signs of Lymphoma in dogs and cats

The 10 signs to watch for are listed below. Any one of them is a reason to consult your nearby vet; none of them is a diagnosis.

• Firm, painless swellings under the jaw, in front of the shoulders or behind the knees
• Swellings that grew over days to weeks and do not hurt
• Weight loss with a normal or reduced appetite
• Drinking and urinating far more than usual
• Vomiting, diarrhoea or dark stools that will not settle
• Laboured or fast breathing, or a cough, especially in a young cat
• Flat, tired, unwilling to walk as far as usual
• Red, scaly, crusting or ulcerated skin patches that do not respond to treatment
• Lumps or plaques in the skin, at the lips or at the gum margin
• A fever, or more than a tenth of body weight lost

Breeds on this site that document this condition

Read the denominators before you compare these cards, because they are not measuring the same thing. Three of them, the Boxer, the Bulldog and the Bullmastiff, rest on one UK insurance study that found a significant breed effect across 103 diagnoses in 130,684 dogs but published no separate rate for any single breed. The Bernese and Mastiff figures are shares of cancer deaths in owner-reported mortality surveys, not risks of getting the disease. The Manchester Terrier figure is an incidence rate per dog-year from a national registry, and its confidence interval spans a factor of seven. The Siamese and Oriental figures describe the breed mix inside one anatomical form, mediastinal lymphoma, and say nothing about lymphoma overall. The two breeds Indian homes own most are missing on purpose: no source opened for this page reports a within-breed lymphoma rate for the Labrador Retriever, and the Golden Retriever Lifetime Study publishes 500 cumulative diagnoses of four cancers taken together rather than a lymphoma figure of its own. No Indian study gives a breed breakdown at all.

What lymphoma is, and which dogs and cats get it

Lymphoma is a cancer of lymphocytes, the white cells that live in lymph nodes, spleen, liver, bone marrow, gut wall and skin, which is why it can appear almost anywhere and why surgery alone rarely answers it. In dogs it accounts for 24 percent of all documented neoplasms and 85 percent of diagnosed blood-cell malignancies.

The scale is worth stating with a denominator rather than as an adjective. In UK first-opinion practice, VetCompass identified 286 presumed newly diagnosed cases during 2013 among 455,553 dogs, an incidence risk of 63 per 100,000 dogs a year, of which 193 (67 percent) were laboratory-confirmed, giving a confirmed rate of 42 per 100,000 dogs a year. The MSD Veterinary Manual puts the reported incidence at approaching 0.1 percent of susceptible dogs, which is the same order of magnitude read a different way. In cats, lymphoma is the most commonly diagnosed tumour of all, accounting for 30 percent of feline malignancies.

Age is the strongest single predictor in both species, and it is not absolute. The UK primary-care study found dogs older than 12 years and dogs weighing more than 30 kg significantly more likely to be diagnosed, and the UK insurance study found incidence climbing with age to a peak at 10 years. Australian records put feline cases at a median 11.7 years against 9.0 years in the control population, and at a median 3.7 kg against 4.0 kg, so affected cats were older and lighter. Against that, the median age of cats with mediastinal lymphoma in a UK referral series was 3 years, with a bimodal distribution peaking at 1 year, and the average age at diagnosis in 55 Bullmastiff cases was under 6 years. A young animal is not exempt.

Breed risk is real and it is unevenly documented, which is a different thing from being evenly distributed. The MSD manual names the Boxer, Rottweiler and Golden Retriever as breeds that may be at increased relative risk while stating that any breed can be affected. The two breeds Indian homes own most are the awkward case. No source opened for this page gives a within-breed lymphoma rate for the Labrador Retriever, and the Golden Retriever Lifetime Study, which follows more than 3,000 dogs, reports 500 cumulative diagnoses of hemangiosarcoma, lymphoma, high-grade mast cell tumour and osteosarcoma taken together rather than a lymphoma count of its own. A well-known predisposition and a published rate are not the same claim.

B cell and T cell, which is the fork in the road

Immunophenotype divides lymphoma into two diseases that look identical in the consulting room and behave differently afterwards. B-cell lymphoma accounts for 60 to 80 percent of canine cases, T-cell for 10 to 38 percent, mixed populations for 22 percent and null-cell tumours for under 5 percent. The South African series immunophenotyped 119 of its 342 cases (35 percent) and found 82 B-cell (69 percent), 34 T-cell (29 percent) and three neither (2 percent), with diffuse large B-cell lymphoma making up 66 of the 88 cases (75 percent) that had a World Health Organization subtype recorded.

The two most reliable prognostic factors in canine lymphoma are immunophenotype and WHO substage, and dogs with CD3-positive T-cell tumours have significantly shorter remission and survival times. Most T-cell lymphomas are aggressive CD4-positive, CD45-positive high-grade tumours with a median survival of 159 days; a minority are CD4-positive, CD45-negative and run an indolent course. That is why the question 'is it B or T' is worth asking before you commit money to a protocol, and why the UK primary-care authors flagged that few dogs are immunophenotyped at all.

Nobody can tell you what caused it, and that matters because owners look for a reason. The review names a deranged immune system as a contributor and the Indian series notes that immune-mediated disorders such as immune-mediated thrombocytopenia co-occur with lymphoma more often than chance. In cats the one large, historically measured cause is a virus, covered further down this page. Beyond that, the honest answer given by the sources here is that the aetiology of most cases is unknown.

The four forms, and why the form changes everything

Lymphoma is classified by where it sits, and the four forms differ in what an owner notices, how fast it moves and what treatment can do. Multicentric lymphoma, the swollen-lymph-nodes form, is by far the commonest in dogs; in cats the gut form now dominates.

Multicentric disease accounts for 84 percent of canine lymphoma in one review's headline figure, with a published range of 53 to 83 percent across the studies it cites, which is a spread worth printing rather than averaging. The Indian series puts the multicentric share at about 75 percent of all canine lymphoma cases. What owners see is a superficial, painless lymphadenopathy, most often at the mandibular and prescapular nodes, with liver and spleen enlargement and bone marrow involvement following.

Why the cutaneous form is the one that gets missed

Cutaneous epitheliotropic T-cell lymphoma arrives as a skin disease and is treated as one for months. Across 30 European cases the median time between onset and a final diagnosis was 5 months, with a range from 0 to 12 months, and the commonest lesions were diffuse erythema in 86.6 percent, scaling in 60 percent and focal hypopigmentation in 50 percent. Mucocutaneous junctions or mucosae were affected in half the cases, and immunohistochemistry confirmed T-cell neoplasia in all 30. Early solar dermatitis, pyoderma, ringworm and autoimmune skin disease all look like it, and only a biopsy separates them.

The Indian series is the clearest demonstration of what that delay costs. Of the eight dogs it enrolled at the Madras Veterinary College Teaching Hospital, six had multicentric disease and two had cutaneous disease diagnosed as CD3-positive epitheliotropic T-cell lymphoma on punch biopsy and immunohistochemistry. Every one of the six multicentric dogs survived the full 19 weeks of treatment. Both cutaneous dogs died, one within three days of starting therapy and one after an excellent resolution to week three followed by a sudden flare. The authors attribute the split to the known poorer response of T-cell lymphoma to CHOP-based protocols.

Mediastinal lymphoma is the form that turns into an emergency, because the mass and the fluid around it compress the lungs. It made up 20 to 40 percent of feline cases in the United States, 10 to 50 percent in the United Kingdom and 70 percent in Japan before feline leukaemia virus vaccination began in 1985, and under 15 percent of US cases by 1998 and 2005. A young cat that is breathing hard and eating less is the presentation to act on the same day, not the one to watch for a week.

What you will notice, and when it stops being a this-week problem

The first sign of lymphoma in most dogs is a firm, painless lump where a lymph node sits, under the jaw, in front of the shoulder blade or behind the knee, that grew over days to weeks and does not hurt when you touch it. That is a see-your-vet-this-week finding. Four specific presentations are not.

The general signs are not specific to cancer, which is exactly the problem. Anorexia, weight loss, vomiting, diarrhoea, emaciation, ascites, laboured breathing and fever all occur, and dogs with T-cell disease are more likely to show systemic signs such as anaemia, drinking more and urinating more, largely because raised blood calcium travels with that immunophenotype. Anaemia itself is reported in 30 to 77 percent of cases across studies and predicts a worse outcome.

• A swelling that is painless and symmetrical beats one that hurts, because an abscess or a reactive node from a tooth or a tick-borne infection is usually sore and usually one-sided, while a lymphoma node is firm, painless and often several at once.
• A young cat breathing fast or hard is a same-day call, since the median age in a 55-cat mediastinal series was 3 years and the mass sits where it can compress the lungs.
• Drinking and urinating heavily alongside swollen lymph nodes points at raised calcium, which is almost exclusively associated with T-cell lymphoma and can cause serious cardiac, gastrointestinal and kidney effects.
• More than a tenth of body weight lost, or a fever, changes the substage letter, and substage b carries a worse outcome than substage a.
• A skin lesion that has not responded to two courses of treatment needs a biopsy, not a third course, given a median 5 months from onset to diagnosis in cutaneous cases.

Two things on this list are frequently mistaken for something else in Indian clinics, and both are worth naming. Generalised lymph node enlargement is a feature of tick-borne disease as well as of cancer, so a dog with big nodes and a fever in a high-tick month is genuinely ambiguous and deserves both a blood smear and an aspirate rather than one or the other. And a bleeding, ulcerated mass at the vulva or prepuce in a free-roaming dog is far more likely to be a transmissible venereal tumour than lymphoma, which is a different tumour with a different treatment and a far better outlook.

How lymphoma is confirmed, and what the aspirate cannot tell you

A fine-needle aspirate of an enlarged node is the first and usually the decisive test, because it is rapid, sensitive and minimally invasive for high-grade lymphoma and needs no anaesthetic. It is also cheap in India, which changes what is reasonable to ask for. What it cannot reliably do is diagnose low-grade disease or tell you the immunophenotype.

The work-up as the sources describe it starts with a physical examination, a complete blood count including platelets, and a serum biochemistry panel that includes total or ionised calcium. Most animals show a mild to moderate non-regenerative anaemia, mild thrombocytopenia is frequent and usually silent, and proteinuria is common. Purdue's staging list for owners is blood tests, urinalysis, chest and abdominal radiographs, an abdominal ultrasound scan and a bone marrow aspirate, with abnormal organs sampled by needle to confirm involvement.

Cytology has a known ceiling. It may be inadequate for low-grade lymphoma or for characterising atypical lymphoid proliferations, and histology enhances the diagnosis of low-grade disease and allows subclassification. Flow-cytometric immunophenotyping raises the diagnostic yield of an aspirate and can subclassify high-grade lymphoma without a surgical biopsy. On tissue, CD3 and CD79a antibodies are considered sufficient for routine patient care, with CD20, CD21 and PAX5 used for B cells and CD4 and CD8 for T cells.

Even the specialists disagree, and the number is published

A study run by the American College of Veterinary Pathologists oncology committee gave 300 canine lymphoma biopsies to 20 pathologists, three of whom set the consensus diagnosis, and asked the other 17 to choose from a list of 43 B-cell and T-cell entities. Overall accuracy against the consensus was 83 percent, rising to 87 percent when the analysis was limited to the six commonest diagnoses, which held 80 percent of all cases. When 5 percent of cases were reintroduced under a different identity, agreement between a pathologist's first and second reading of the same slide ranged from 40 to 87 percent. That is the honest state of the art, and it is a reason to ask what a report is confident about rather than to distrust it.

Imaging earns its place for staging rather than for diagnosis. Thoracic radiographs show lymphadenopathy, pulmonary infiltration or a cranial mediastinal mass in 70 percent of canine multicentric cases, and abdominal ultrasonography assesses node size and architecture and picks up splenic and hepatic involvement. In the Indian series, ultrasound of every dog showed enlarged mesenteric nodes and a honeycomb pattern in the spleen.

One genetic result changes how a dog can be treated, and it has nothing to do with the cancer. The Washington State University veterinary clinical pharmacology laboratory lists doxorubicin, vincristine, vinblastine and vinorelbine under chemotherapy on its MDR1 problem-drug list, and directs prescribers to seek specific guidance for a dog carrying the mutation. Three of the four CHOP drugs are on that list. If your dog is a Collie, Australian Shepherd, Shetland Sheepdog or another herding breed, MDR1 drug sensitivity is worth establishing before the first infusion rather than after it.

Staging and substage, and what you are actually consenting to

Staging means finding out how much of the body the lymphoma occupies, on a World Health Organization scale from I to V, with a lower-case letter after it for whether the animal is systemically unwell. The letter is the part most owners are never told about, and it is one of the two most reliable prognostic factors there are.

More than 80 percent of dogs are already at stage III to V when they are diagnosed. That single figure should stop an owner blaming themselves for a late catch, because a painless node that grows over two weeks in an animal that is otherwise eating and playing is not a thing most people notice earlier. The Indian series is a clean example: all eight dogs were characterised as grade IV subtype a, so every one of them arrived with abdominal organ involvement while showing no systemic signs at all.

Stage and substage are not equally important. Stages I and II do better than later stages, and substage b does worse than substage a, with the review naming immunophenotype and WHO substage together as the two most reliable prognostic factors. An animal that is eating, playing and afebrile with stage IV disease is in a materially different position from one that has lost a tenth of its weight, and the stage number alone hides that.

What a full staging work-up costs you, and not only in money

Consenting to staging means consenting to a specific list. Purdue's owner-facing list is blood tests, a urinalysis, chest and abdominal radiographs, an abdominal ultrasound scan and a bone marrow aspirate, with needle sampling of any organ that looks abnormal on the scan. The bone marrow aspirate is the one that usually needs sedation. A computed tomography scan gives a full-body image and can find further sites, at a cost the review describes as high but possibly worthwhile.

1. Ask what each staging test would change. If a result will not alter the protocol, the budget or your decision, it is reasonable to ask whether it can wait. The AAHA oncology guidelines frame therapy as being based on tumour type, grade and stage established by cytology or histology combined with imaging and lymph node sampling, which is the set that does change decisions.
2. Ask for the immunophenotype specifically. It is one of the two strongest predictors and the UK primary-care study found few dogs get it.
3. Ask for the substage letter in writing. A dog recorded as stage IV substage a and a dog recorded as stage IV substage b have different expected outcomes.
4. Ask what happens if you stop partway. Every protocol in the table further down has a defined length, and a course abandoned at week six is not the course the median was measured on.
5. Ask whether your vet will run it or refer it. In UK primary-care practice only 18 of the 286 dogs identified, which is 6 percent, were referred to a specialist clinic at all, so being treated by a general practitioner is normal rather than second best.

What treatment is, in general terms, and what each protocol actually bought

Chemotherapy is the treatment for lymphoma because the disease is systemic, and multi-agent protocols outperform single agents. The standard is CHOP, an acronym for a combination of cyclophosphamide, doxorubicin, vincristine and prednisolone given in rotation, which Purdue calls its gold standard over 25 weeks. This page names drug classes and protocol names and never a dose, because the dose is the veterinarian's decision for the animal in front of them.

Start from the untreated figure, because every other number is measured against it. Reported survival in untreated canine lymphoma is 4 to 6 weeks after diagnosis. Conventional CHOP-based regimens induce remission in 80 to 95 percent of dogs, with overall median survival times of 8 to 12 months, and 20 to 25 percent of treated dogs are expected to survive two years from the start of treatment. Purdue gives the median survival on CHOP as 9 to 13 months and 70 to 90 percent achieving complete or partial remission, most of them complete.

Read that table as a ranking of protocols and you will misread it. These are medians from different studies in different populations with different case mixes, not a head-to-head trial, and the review presents them as a summary of the clinical routine rather than as a comparison. What the table does show reliably is the shape of the decision: a multi-agent course buys roughly three to four times the untreated survival, and a single-agent course buys less but costs less and asks fewer visits of you.

Shorter protocols are not obviously worse

A 15-week CHOP protocol in 31 client-owned dogs produced an overall response rate of 100 percent and a median progression-free interval of 140 days, with a 95 percent confidence interval of 91 to 335 days. The striking finding was that dose intensity did not correlate with outcome, and dogs that had two or more treatment delays had significantly longer progression-free and overall survival, which the authors read as those dogs receiving their own maximum tolerated dose while dogs with no adverse effects may have been underdosed. A separate 30-dog study of a 15-week protocol reported an objective response rate of 100 percent with a median progression-free interval of 171 days and a median overall survival of 254 days.

Radiotherapy has a narrow but real role, and it is the treatment India can least often supply. Because lymphoma is systemic, radiation is used as whole-body or, more usually, half-body irradiation in two sessions, alongside or after a CHOP protocol. Studies using it during a CHOP protocol reported a median first remission of 455 days and a median overall survival of 560 days; used at the end of the protocol, 311 days and 486 days; and with a low-dose-rate half-body schedule during CHOP, 410 days and 684 days.

Immunotherapy is not yet an option for a dog in India or anywhere else in routine practice. Rituximab and other antibodies designed against human and mouse CD20 do not bind canine CD20 despite the epitopes being conserved, so the approach that transformed human B-cell lymphoma does not transfer, and there is a scarcity of monoclonal antibodies designed for veterinary use. Rabacfosadine was, as the 2025 review records it, the first and only fully United States FDA-approved treatment for canine lymphoma; no Indian source opened for this page names it, so treat it as not obtainable here until a supplier says otherwise.

Side effects are the thing owners fear most and the thing the evidence is calmest about. Neutropenia is the usual dose-limiting toxicity, bone marrow suppression and gastrointestinal effects such as vomiting and diarrhoea are the common ones, and in cats side effects generally occur in about 1 in 5 of those treated. Roughly 75 to 80 percent of dogs experience no significant side effects at all, and about 5 percent have effects serious enough to need hospitalisation. Most dogs do not lose their fur.

Declining treatment is a legitimate choice, and palliative care has its own evidence

Choosing not to pursue chemotherapy is a legitimate decision and not a failure of love. Most Indian owners will not have a full CHOP protocol within reach, and a page that only describes the expensive path is not describing their situation. Here is what the evidence says about the other one.

Be clear-eyed about what declining means. Untreated, most dogs live roughly four to six weeks after diagnosis, which matches the 4 to 6 weeks the review reports. Palliative care focuses on appetite, comfort and quality of time. Families choose it for a dog's age, for other illnesses, for financial reality, for temperament, or simply for a belief about what their particular animal would want, and nobody should be made to feel guilty about it.

There is also a middle path that the survival table already shows. A steroid used on its own shrinks nodes within days and makes a dog feel better quickly, at a median survival of roughly one to three months, and a single-agent doxorubicin course sits at a median survival of 169 days in the review's table. The review names the single-agent doxorubicin protocol as the most effective of the single agents and a reasonable option where there are financial or time limitations, and as one that may be recommended where treatment is primarily palliative. The MSD manual frames the whole exercise the same way, stating that given only a small fraction of dogs achieve a cure with conventional treatment, the primary goal of treatment is palliative.

What owners who did treat actually reported afterwards

Two owner surveys measured the thing the clinical papers do not. In a Cambridge study, the owners of 25 dogs with multicentric lymphoma on multidrug chemotherapy were interviewed: 68 percent considered their dog's quality of life to be the same as before the lymphoma, the other 32 percent judged it acceptable but poorer, 52 percent reported treatment complications, and 92 percent had no regrets about treating. In a Munich survey of the owners of 207 dogs treated over 13 years, 123 owners (59.4 percent) responded; quality of life improved during chemotherapy in 64 dogs (53.3 percent) and declined in 24 (20.0 percent), the overall remission rate was 83.7 percent, 65.0 percent of owners were satisfied and 73.2 percent would treat again.

Those two studies are the best answer to the fear that treatment means a miserable animal, and they are also the best argument for monitoring rather than assuming. In the Munich survey the 20 percent whose quality of life declined did so in direct correlation with remission status and side effects, which is a measurable, reviewable thing rather than an inevitability. The clinical relevance the authors draw is that quality of life needs constant monitoring during palliative chemotherapy, and that the assessment is what lets an owner and a veterinarian choose the next step together.

Cats, feline leukaemia virus, and why the picture changed

Feline lymphoma was historically a retrovirus disease, and it is much less so now. In the 1980s, before widespread vaccination, approximately 70 percent of cats with lymphoma were feline leukaemia virus antigenaemic. The virus is still a real risk factor; it is no longer the majority story.

The association itself is well measured. A retrospective study of sera from 353 cats with naturally occurring feline leukaemia virus infection, collected in Boston, Los Angeles, New York City and Seattle between 1968 and 1988, compared 53 cats with leukaemia or lymphoma against matched controls and confirmed a strong correlation between feline leukaemia virus viraemia and leukaemia or lymphoma, along with a significant and independent correlation between feline immunodeficiency virus infection and lymphoproliferative malignancy. Fifty-one of the 353 feline leukaemia virus positive sera, 14.4 percent, also carried antibodies to feline immunodeficiency virus.

Vaccination, testing and quarantine changed the disease rather than abolishing it. A 21-year survey of the teaching hospital caseload at the University of California, Davis, covering 1983 to 2003, confirmed a significant decrease in the importance of virus-associated types, and found that despite that decrease the overall incidence of lymphoma in cats treated there rose between 1982 and 2003, driven largely by intestinal lymphoma and to a lesser degree by atypical forms. The same survey observed a high incidence of mediastinal lymphoma in young Siamese or Oriental breeds.

The UK referral series shows the same shift as a set of proportions. Of 55 cats with mediastinal lymphoma seen between 1998 and 2010, only 5 (9.0 percent) were feline leukaemia virus antigen positive and 2 (3.6 percent) were feline immunodeficiency virus antibody positive, while 48 (87.4 percent) were negative for both. Against that, the mediastinal form made up 20 to 40 percent of United States feline lymphoma cases and 70 percent of Japanese cases before vaccination began in 1985, and under 15 percent of US cases by 1998 and 2005.

Why the Indian boundary is different, and where it is drawn

One large study disagrees with the rest, and the disagreement is worth publishing rather than resolving. The Australian series of 1,705 cases against 85,741 controls found the Siamese at increased risk of lymphoma overall, with an odds ratio of 2.6, a 95 percent confidence interval of 2.0 to 3.3 and p below 0.001 across 68 Siamese cases, and it found male cats at increased risk with an odds ratio of 1.2. But its authors state plainly that the association between Siamese cats and mediastinal disease reported previously was not identified in their data, while the previously reported association with nasal disease was. So a UK referral series and an Australian population study agree that the Siamese is over-represented and disagree about where the disease turns up. Both are printed here, with their populations named, because a referral caseload and a registry are not the same denominator.

India is not the post-vaccination United Kingdom. Feline leukaemia virus vaccination is not a routine part of most Indian cat protocols, free-roaming and semi-owned cats are the norm rather than the exception, and the retroviral status of a cat presented with a mediastinal mass in Chennai or Kolkata cannot be assumed from a UK referral series. What can be carried across is the direction of the association, not the proportions. The retroviral picture itself belongs to FeLV and FIV in cats, and what matters on this page is the boundary: a cat diagnosed with lymphoma should be tested for both viruses, because the result changes the household advice even where it does not change the protocol.

Retroviral status also does not mean a cat cannot be treated. A Thai retrospective study of 92 cats with mediastinal lymphoma, every one of them feline leukaemia virus antigen positive, treated with a cyclophosphamide, vincristine and prednisolone protocol, reported a response rate of 96.74 percent, made up of 81.52 percent complete response, 15.22 percent partial response and 3.26 percent no response, with an overall median survival time of 338 days and a range of 62 to 1,057 days. Cats under 4 years survived longer than those aged 4 or more, and anaemia before treatment, azotaemia after the second induction and a raised alanine aminotransferase after the first were each associated with an increased chance of death. In the UK series, retroviral status did not affect response or survival at all.

The feline gut form has its own, gentler evidence, and it is the one most relevant to an older Indian house cat losing weight. Forty-one cats with histologically confirmed low-grade lymphocytic lymphoma treated with a steroid and an oral alkylating agent achieved a complete response in 56 percent and a partial response in 39 percent, with lymphoma confined to the gastrointestinal tract in 68 percent; median remission was 897 days for complete responders against 428 days for partial responders, and overall median survival was 704 days. A second series of 28 cats with small-cell gastrointestinal lymphoma on the same combination reported a 96 percent clinical response rate and a median clinical remission of 786 days. Common signs in the 41-cat series were weight loss in 83 percent, vomiting in 73 percent, anorexia in 66 percent and diarrhoea in 58 percent, and 78 percent of the cats tested had low serum cobalamin.

Those feline numbers are worth setting against the canine ones deliberately. A cat with low-grade gut lymphoma on two oral drugs has a published median survival of 704 days, which is longer than any canine protocol in the review's table, and the treatment is tablets and monitoring rather than a weekly infusion schedule. That is the single most useful thing an Indian cat owner can know, because it is the form of this disease most likely to be both diagnosable and treatable where they live.

What it costs in India, and what is actually obtainable

Two Indian sources publish a price for treating cancer in a dog, and they disagree by a factor of five, so this page prints both with their dates. Diagnosis, by contrast, is cheap and genuinely obtainable, because two government veterinary universities publish their rate cards and both price a cytology at under the cost of a restaurant meal.

The older figure comes from the Tata Memorial Centre itself. A press item filed on 24 June 2015 and reproduced on the ACTREC site states that cancer care for dogs at ACTREC costs between Rs 40,000 and Rs 60,000 depending on treatment cycles such as chemotherapy or radiation, that the centre treated nearly 150 dogs in the previous year, and that nearly 50 dogs underwent chemotherapy in that year. Those figures are eleven years old and should be read as a floor rather than as a current quotation.

The current figure comes from a Bengaluru animal charity. Its page of 15 June 2026, medically reviewed by a named veterinary officer, prints a cost table headed Price Range (INR) giving a full CHOP protocol for canine lymphoma at a specialist oncology centre at Rs 80,000 to Rs 3,00,000 or more, and an individual drug infusion session at Rs 5,000 to Rs 25,000 or more per session depending on drug and facility. Every rupee figure on this page has been divided by 84.38 and by 74 to check it is an Indian price rather than a converted dollar list; Rs 80,000 is about 948 or 1,081 US dollars on those two rates and Rs 3,00,000 is about 3,555 or 4,054, neither of which is a round dollar number, so the range is native.

Set the two ranges against each other and the picture is uncomfortable rather than reassuring. The top of the published Indian range, Rs 3,00,000, is roughly 3,555 US dollars at 84.38 to the dollar, which is below the bottom of the American range of about 4,000 dollars Voice of Stray Dogs (VOSD). In other words Indian specialist chemotherapy is cheaper in absolute terms and is not affordable relative to Indian incomes, which is the real reason most Indian dogs with lymphoma are not treated on a full protocol.

The part that is genuinely cheap, and the part that is not

Diagnosis is not the barrier in India. At ICAR-IVRI Izatnagar, an aspirate cytology, a histopathology and a cytology each cost Rs 150 for a pet animal, an ultrasound scan Rs 250 and a complete blood count Rs 300, all plus tax, on the rate card effective June 2024. At Madras Veterinary College the published hospital fee is Rs 100 for a seven-day small animal registration, Rs 300 for a scan, Rs 100 for an x-ray and Rs 50 for haematology, biochemistry, urine or culture. The IVRI polyclinic page names cancer diagnosis and treatment among its super-specialised services, and the Madras Veterinary College clinics page names oncology among the faculty's disciplines.

Drugs are the other thing India quietly does well, in the one place that publishes it. The Madras Veterinary College Teaching Hospital pharmacy runs on an average annual budget of Rs 25,00,000 and dispenses drugs and fluids free of cost for the treatment of animals brought to the hospital. That is the setting in which the only published Indian lymphoma case series was run, and it is why the question 'is a cyclophosphamide-based protocol obtainable in India' has a demonstrated answer rather than a theoretical one.

What this page could not find a price for, anywhere, is radiotherapy for an animal in India as a current published rate. The 2015 ACTREC figure bundles radiation into a Rs 40,000 to Rs 60,000 range for cancer care generally, and the private specialist practice that now offers radiation publishes no prices at all on its site. Treat any current radiotherapy figure you are quoted as a quotation from that clinic and not as a national rate, and ask for it in writing. Pet insurance may or may not help; the wordings are compared on the pet insurance in India guide rather than here.

What is different about lymphoma in India

Veterinary oncology exists in India at a handful of addresses, and everywhere else the realistic choice is between diagnosis with palliative care and referral to another city. That is the honest framing, and it is the one no ranking page offers.

Start with what is documented rather than with what is assumed. The Tata Memorial Centre's ACTREC campus at Kharghar in Navi Mumbai was described in its own press item of 24 June 2015 as offering chemotherapy and radiotherapy for canines and as the only such unit in the country. The same item names Dr Pradip Chaudhari as the veterinary oncologist there, records that the centre treated nearly 150 dogs in the preceding year with nearly 50 undergoing chemotherapy, and quotes an expert saying that most city veterinary doctors are unaware that the treatment is available in India at all.

A second address has appeared since. The Cancer Vet runs clinics in Chembur in Mumbai and in Pimpri-Chinchwad, Maharashtra, near Pune, offering cancer diagnosis, chemotherapy, radiation therapy, surgical treatment and tele-consultations, founded by a board-certified veterinary radiation oncologist. A trade report of 9 February 2024 gives that founder's training route, a fellowship in medical oncology at Michigan State University, specialty training in radiation oncology at what the report prints as the University of Madison-Wisconsin, and a teaching post at The Ohio State University College of Veterinary Medicine before returning to India. Two cities, in a country of a hundred and more that have a veterinary hospital.

The one published Indian case series, and what it actually says

India has exactly one published canine lymphoma case series that this page could find, and it is a good one. Eight dogs presented to the Small Animal Outpatient Medical and Dermatology Unit of the Madras Veterinary College Teaching Hospital in Chennai, Tamil Nadu, during 2019 to 2021 with signs suggestive of lymphoma. Four arrived with anorexia, dullness and mandibular swelling; two arrived with recurrent non-healing wounds without itching and occasional bleeding. All eight had enlargement of all lymph nodes including the inguinal nodes, aspirate cytology showed pleomorphic lymphocytes, and abdominal ultrasound showed enlarged mesenteric nodes with a honeycomb splenic pattern, characterising them as grade IV subtype a.

The outcome is the part worth carrying. All eight were treated on the University of Wisconsin-Madison CHOP-19 protocol, clinical remission defined as the complete absence of clinical signs was achieved in all dogs within the third week of therapy, and the six dogs with multicentric disease survived to the nineteenth week of treatment. One dog developed thrombocytopenia during the third week, at 50,000 platelets per microlitre, so chemotherapy was postponed until the count recovered to 1,40,000 per microlitre a week later, and then resumed. Pre-treatment and post-treatment blood values showed no significant change except for creatinine, which rose significantly but stayed within normal limits.

Two honest caveats belong with that series. Its title counts six dogs and its methods section counts eight, because the two cutaneous cases died before the protocol finished and the title reports the survivors; the presenting-complaint sentence adds up to six rather than eight as well, so the enrolment number is internally inconsistent in the paper as published. And eight dogs at one hospital is a case series, not a prevalence study, so it tells an Indian owner that the protocol can be delivered here and tells them nothing about how common the disease is in India.

That absence is worth stating precisely rather than vaguely. A Europe PMC title-and-abstract search for lymphoma combined with dog, dogs or canine and India returned 0 records on 27 September 2026, and the author-affiliation search returned 6, none of them an Indian clinical case series; the closest was a commentary letter co-authored from Chandigarh University about a Korean study of 77 dogs Jeong SY. Evaluation of factors influencing…. The feline affiliation search returned 19 records that were overwhelmingly Dalton's Lymphoma Ascites mouse pharmacology studies, a transplantable murine tumour line that shares the word lymphoma and nothing else. Controls run through the identical route in the same session returned 110 records for Labrador with hip dysplasia and 39 for parvovirus in dogs in India, so the instrument was working and the absence is real.

• Ask for the aspirate before you ask for the referral. A cytology at a government veterinary college costs Rs 150 plus tax at Izatnagar, and it is the test that decides whether the referral is worth making at all.
• Ask whether your own vet can run the protocol. Only 6 percent of UK primary-care lymphoma dogs were referred to a specialist, so general-practice delivery is the international norm and not an Indian compromise.
• Ask what the whole course costs before the first session, because the published Indian range runs from Rs 80,000 to Rs 3,00,000 or more and the difference is the protocol, the number of sessions and the facility.
• Ask about travel and the weekly visit, since a CHOP course is roughly 15 to 25 weeks of appointments and a humid monsoon week in a city with two specialist clinics is a real logistical cost, not a footnote.
• Ask for the substage letter and the immunophenotype on the report, because those two are the strongest predictors and they are also the two most often left off.

One Indian-specific clinical point deserves its own line. Generalised lymphadenopathy with fever is the presentation of tick-borne disease across most of India as well as of lymphoma, and in a hot, humid month the tick-borne explanation is far more common. That does not make the aspirate unnecessary. It makes it more necessary, because a dog treated for a tick-borne infection whose nodes do not shrink has been given a diagnosis and lost weeks, and the Indian series is a reminder that lymphoma at this hospital presented exactly that way, with anorexia, dullness and mandibular swelling.

Living with it, week by week

A dog or cat in remission from lymphoma lives an ordinary life, and that is the point of treating. The work for an owner is watching the right things, keeping the right appointments, and knowing in advance what a relapse looks like so it is a conversation rather than a shock.

Remission is a defined thing, not a vibe, and it is assessed at every visit. Purdue defines partial remission as the overall cancer burden reduced by at least 50 percent and complete remission as the cancer becoming undetectable to any readily available screening test, with progression meaning the cancer has returned despite chemotherapy. The difference between the two is not cosmetic: across 38 treated cats with mediastinal lymphoma, those achieving a complete response survived a median 980 days against 42 days for a partial response, at p equal to 0.032.

Chemotherapy has phases, and knowing them stops a plateau feeling like a failure. An intensive induction phase aims at complete remission, a less intensive maintenance phase holds it, reinduction follows a relapse, and rescue therapy uses drugs not in the original protocol when the disease no longer responds. Most dogs eventually come out of remission, and a second-line protocol can often achieve a further remission that is usually shorter. Rescue regimens sit at median survivals of 169 to 328 days in the review's table depending on the protocol.

1. Feel the same four node sites once a week, always in the same order, under the jaw, in front of the shoulders, in the groin and behind the knees, because an enlarging node usually means the disease is coming out of remission and is a signal to talk about next steps rather than an emergency.
2. Report a refusal to eat lasting more than 24 hours, repeated vomiting or diarrhoea, unusual lethargy or a fever, which is the escalation list the National Canine Cancer Foundation gives owners.
3. Keep every pre-treatment blood test, since haematology and biochemistry were run the day before each scheduled dose in the Indian series and one dog's treatment was correctly postponed on the result.
4. Weigh the animal at every visit and write it down, because more than 10 percent of body weight lost is one of the three things that moves an animal from substage a to substage b.
5. Keep walks, play and routine going, as most dogs in remission live entirely normal lives and no evidence supports restricting a lymphoma patient's diet in ways that reduce their enjoyment of eating.

Handling cytotoxic drugs at home, which nobody warns Indian owners about

If any part of the protocol is an oral drug given at home, the safety rules are part of the prescription. The AAHA oncology guidelines emphasise methods to protect patient, team and client safety in relation to handling cytotoxic chemotherapeutics, and encourage strengthening the training and responsibilities of veterinary technicians precisely because complex cancer cases are managed by a team. Ask who in your household will handle the tablets, ask what to do about urine and faeces in the days after a treatment, and ask for the instruction in writing. International Cat Care sets out precautions for cats receiving chemotherapy as a section of its own.

Finally, keep the prognosis conversation open rather than settled. The review is explicit that although the curable rate is low, at under 10 percent of cases, complete response and a good quality of life during prolonged remission and survival are common. A Korean review of 77 dogs found that strict adherence to the therapeutic protocol and the use of multiple agents as a rescue protocol were both important in prolonging survival time, and identified leucocyte and platelet abnormalities as negative prognostic factors. Those are things you and your veterinarian influence together, which is more than can be said for the stage at diagnosis.